Arianna Huffington's Thrive Global partners with Zepbound-maker Eli Lilly to share content on healthy habits where patients ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. And retail traders should know. We ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price ...

Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...

This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...

Colulintide is under clinical development by Eli Lilly and Co and currently in Phase I for Obesity. According to GlobalData, Phase I drugs for Obesity have a 59% phase transition success rate (PTSR) ...

Kinsula (donanemab-azbt), Eli Lilly’s Alzheimer’s medication, has been approved by China’s National Medical Products Administration. In addition, EVA Pharma, in collaboration with Eli Lilly ...

Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops, and markets human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, ...